AstraZeneca PLC (LON:AZN) Announces Dividend of GBX 77.60

AstraZeneca PLC (LON:AZN) declared a dividend on Thursday, July 25th, Upcoming.Co.Uk reports. Shareholders of record on Thursday, August 8th will be given a dividend of GBX 77.60 ($0.99) per share by the biopharmaceutical company on Monday, September 9th. This represents a yield of 0.64%. The ex-dividend date of this dividend is Thursday, August 8th. The official announcement can be seen at this link.

AstraZeneca Stock Performance

Shares of LON:AZN opened at £126.04 ($161.07) on Wednesday. The company has a market capitalization of £195.36 billion, a price-to-earnings ratio of 4,008.33, a P/E/G ratio of 0.97 and a beta of 0.16. The firm’s 50 day simple moving average is £122.95 and its 200 day simple moving average is £113.85. The company has a debt-to-equity ratio of 92.51, a current ratio of 0.89 and a quick ratio of 0.59. AstraZeneca has a fifty-two week low of GBX 9,461 ($120.91) and a fifty-two week high of £127.84 ($163.37).

Analyst Upgrades and Downgrades

A number of research firms have issued reports on AZN. Jefferies Financial Group boosted their target price on AstraZeneca from GBX 71 ($0.91) to GBX 74 ($0.95) and gave the company a “hold” rating in a research note on Tuesday, July 2nd. Shore Capital reiterated a “buy” rating on shares of AstraZeneca in a report on Thursday, July 25th. Citigroup restated a “buy” rating on shares of AstraZeneca in a report on Tuesday, May 28th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a £110 ($140.58) target price on shares of AstraZeneca in a research note on Tuesday, June 18th. Finally, Berenberg Bank reissued a “buy” rating and issued a £150 ($191.69) target price on shares of AstraZeneca in a research report on Monday. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of £105.53 ($134.87).

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.